Considering the critical interface between tumor cells and stromal cells in the search for targets for anticancer therapy

Cancer Cell. 2005 May;7(5):408-9. doi: 10.1016/j.ccr.2005.04.024.

Abstract

In this issue of Cancer Cell, a paper by Lynch et al. demonstrates how the careful study of changes that occur at the interface between tumor cells and stromal cells led to the discovery of a new function for matrix metalloproteinase-7 (MMP-7) in the formation of osteolytic lesions in prostate cancer. The data suggest that MMP-7 inhibition could be a therapeutic target in prostate cancer.

Publication types

  • Comment

MeSH terms

  • Animals
  • Carrier Proteins / metabolism
  • Gene Expression
  • Male
  • Matrix Metalloproteinase 7 / genetics
  • Matrix Metalloproteinase 7 / metabolism*
  • Membrane Glycoproteins / metabolism
  • Mice
  • Models, Biological
  • Osteoclasts / metabolism
  • Osteoclasts / pathology
  • Osteolysis / etiology
  • Osteolysis / metabolism
  • Osteolysis / pathology
  • Prostatic Neoplasms / complications
  • Prostatic Neoplasms / metabolism
  • Prostatic Neoplasms / therapy*
  • RANK Ligand
  • Rats
  • Receptor Activator of Nuclear Factor-kappa B
  • Stromal Cells / metabolism*

Substances

  • Carrier Proteins
  • Membrane Glycoproteins
  • RANK Ligand
  • Receptor Activator of Nuclear Factor-kappa B
  • Tnfrsf11a protein, mouse
  • Tnfsf11 protein, mouse
  • Matrix Metalloproteinase 7